FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318197064> ?p ?o ?g. }

• W4318197064 abstract "Background Immune checkpoint inhibitors (ICIs) have shown unprecedented clinical benefit in cancer immunotherapy and are rapidly transforming the practice of advanced lung cancer. However, resistance routinely develops in patients treated with ICIs. We conducted this retrospective study to provide an overview on clinical characteristics of ICI resistance, optimal treatment beyond disease progression after prior exposure to immunotherapy, as well as potential prognostic factors of such resistance. Methods 190 patients diagnosed with unresectable lung cancer who received at least one administration of an anti-programmed cell death 1 (PD-1)/anti-programmed cell death-ligand 1(PD-L1) at any treatment line at Zhongshan Hospital Fudan University between Sep 2017 and December 2019 were enrolled in our study. Overall survival (OS) and progression-free survival (PFS) were analyzed. Levels of plasma cytokines were evaluated for the prognostic value of ICI resistance. Results We found that EGFR/ALK/ROS1 mutation and receiving ICI treatment as second-line therapy were risk factors associated with ICI resistance. Patients with bone metastasis at baseline had a significantly shorter PFS1 time when receiving initial ICI treatment. Whether or not patients with oligo-progression received local treatment seemed to have no significant effect on PFS2 time. Systemic therapies including chemotherapy and anti-angiogenic therapy rather than continued immunotherapy beyond ICI resistance had significant effect on PFS2 time. TNF, IL-6 and IL-8 were significantly elevated when ICI resistance. Lower plasma TNF level and higher plasma IL-8 level seemed to be significantly associated with ICI resistance. A nomogram was established to prognosis the clinical outcome of patients treated with ICIs. Conclusion Patients with EGFR/ALK/ROS1 mutation, or those receiving ICI treatment as second-line therapy had higher risk of ICI resistance. Patients with bone metastasis had poor prognosis during immunotherapy. For those patients with oligo-progression after ICI resistance, combination with local treatment did not lead to a significantly longer PFS2 time. Chemotherapy and anti-angiogenic therapy rather than continued immunotherapy beyond ICI resistance had significant effect on PFS2 time. Levels of plasma cytokines including TNF, IL-6 and IL-8 were associated with ICI resistance." @default.
• W4318197064 created "2023-01-27" @default.
• W4318197064 creator A5019766538 @default.
• W4318197064 creator A5042678330 @default.
• W4318197064 creator A5045939244 @default.
• W4318197064 creator A5053086539 @default.
• W4318197064 creator A5056388603 @default.
• W4318197064 creator A5063163553 @default.
• W4318197064 creator A5064222660 @default.
• W4318197064 creator A5065304323 @default.
• W4318197064 creator A5068465620 @default.
• W4318197064 creator A5091260655 @default.
• W4318197064 date "2023-01-26" @default.
• W4318197064 modified "2023-10-01" @default.
• W4318197064 title "Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy" @default.
• W4318197064 cites W2012295597 @default.
• W4318197064 cites W2108933323 @default.
• W4318197064 cites W2128395874 @default.
• W4318197064 cites W2321170268 @default.
• W4318197064 cites W2342050914 @default.
• W4318197064 cites W2400514548 @default.
• W4318197064 cites W2747294052 @default.
• W4318197064 cites W2750858918 @default.
• W4318197064 cites W2778781711 @default.
• W4318197064 cites W3021646013 @default.
• W4318197064 cites W3039320004 @default.
• W4318197064 cites W3093708469 @default.
• W4318197064 cites W3110987629 @default.
• W4318197064 cites W3162453019 @default.
• W4318197064 doi "https://doi.org/10.3389/fimmu.2023.1089026" @default.
• W4318197064 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36776868" @default.
• W4318197064 hasPublicationYear "2023" @default.
• W4318197064 type Work @default.
• W4318197064 citedByCount "1" @default.
• W4318197064 countsByYear W43181970642023 @default.
• W4318197064 crossrefType "journal-article" @default.
• W4318197064 hasAuthorship W4318197064A5019766538 @default.
• W4318197064 hasAuthorship W4318197064A5042678330 @default.
• W4318197064 hasAuthorship W4318197064A5045939244 @default.
• W4318197064 hasAuthorship W4318197064A5053086539 @default.
• W4318197064 hasAuthorship W4318197064A5056388603 @default.
• W4318197064 hasAuthorship W4318197064A5063163553 @default.
• W4318197064 hasAuthorship W4318197064A5064222660 @default.
• W4318197064 hasAuthorship W4318197064A5065304323 @default.
• W4318197064 hasAuthorship W4318197064A5068465620 @default.
• W4318197064 hasAuthorship W4318197064A5091260655 @default.
• W4318197064 hasBestOaLocation W43181970641 @default.
• W4318197064 hasConcept C121608353 @default.
• W4318197064 hasConcept C126322002 @default.
• W4318197064 hasConcept C143998085 @default.
• W4318197064 hasConcept C2776256026 @default.
• W4318197064 hasConcept C2776694085 @default.
• W4318197064 hasConcept C2777701055 @default.
• W4318197064 hasConcept C2780057760 @default.
• W4318197064 hasConcept C2780739268 @default.
• W4318197064 hasConcept C2781053074 @default.
• W4318197064 hasConcept C71924100 @default.
• W4318197064 hasConceptScore W4318197064C121608353 @default.
• W4318197064 hasConceptScore W4318197064C126322002 @default.
• W4318197064 hasConceptScore W4318197064C143998085 @default.
• W4318197064 hasConceptScore W4318197064C2776256026 @default.
• W4318197064 hasConceptScore W4318197064C2776694085 @default.
• W4318197064 hasConceptScore W4318197064C2777701055 @default.
• W4318197064 hasConceptScore W4318197064C2780057760 @default.
• W4318197064 hasConceptScore W4318197064C2780739268 @default.
• W4318197064 hasConceptScore W4318197064C2781053074 @default.
• W4318197064 hasConceptScore W4318197064C71924100 @default.
• W4318197064 hasFunder F4320318548 @default.
• W4318197064 hasFunder F4320321885 @default.
• W4318197064 hasLocation W43181970641 @default.
• W4318197064 hasLocation W43181970642 @default.
• W4318197064 hasLocation W43181970643 @default.
• W4318197064 hasOpenAccess W4318197064 @default.
• W4318197064 hasPrimaryLocation W43181970641 @default.
• W4318197064 hasRelatedWork W2413020017 @default.
• W4318197064 hasRelatedWork W2786497694 @default.
• W4318197064 hasRelatedWork W2796582438 @default.
• W4318197064 hasRelatedWork W2948845624 @default.
• W4318197064 hasRelatedWork W2970048128 @default.
• W4318197064 hasRelatedWork W3127980980 @default.
• W4318197064 hasRelatedWork W3161613553 @default.
• W4318197064 hasRelatedWork W3215044659 @default.
• W4318197064 hasRelatedWork W4247922271 @default.
• W4318197064 hasRelatedWork W4255240967 @default.
• W4318197064 hasVolume "14" @default.
• W4318197064 isParatext "false" @default.
• W4318197064 isRetracted "false" @default.
• W4318197064 workType "article" @default.